A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

NCT02930109 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Leukemia

Interventions

DRUG: PTX-200
DRUG: Cytarabine

Sponsor

Prescient Therapeutics, Ltd.